US government agencies have questioned the legality of cannabidiol (CBD) – just as the industry is starting to see the benefits of increased public awareness.
Actions by both the US Food and Drug Administration (FDA) and the US Drug Enforcement Administration (DEA) have recently cast doubt on the future of CBD, according to speakers at the Marijuana Business Conference (MJBizCon) held May 9th–11th in New Orleans.
The situation is further complicated by the lack of clarity over the status of CBD, as some stakeholders classify it as a drug and others as a dietary supplement. Speakers at the conference also discussed a potential loophole that would allow CBD to be legally sold as a product derived from industrial hemp.
...
Restricted content. Do you want to read more?
Register
Sign up NOW for 7 days FREE TRIAL and access our briefings section
Regulatory report: medical and recreational cannabis – a global overview
CBD-Intel has compiled and classified the regulatory data on medical and recreational cannabis in 50 jurisdictions around the world.
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries using maps, and assesses the likelihood that the status quo may change in the future.
